Table 2 Summary of outcomes in the selected studies
Study | Arm | Follow-up | OS | PFS | ORR | DCR | Incidence of TRAEs | ||
|---|---|---|---|---|---|---|---|---|---|
Median months | Any grade | Grade 3–5 | Death | ||||||
KEYNOTE-181 | PD-1 inhibitor | 7.1 | 8.2 | 2.2 | 16.70% | 46% | 64% | 18.20% | 1.60% |
Chemotherapy | 6.9 | 7.1 | 3.1 | 7.40% | 49.80% | 86% | 40.90% | 1.70% | |
ATTRACTION-3 | PD-1 inhibitor | 10.5 | 10.9 | 1.7 | 19% | 37% | 65% | 18% | 5% |
Chemotherapy | 8 | 8.4 | 3.4 | 22% | 63% | 94% | 63% | 4.30% | |
ESCORT | PD-1 inhibitor | 8.3 | 8.3 | 1.9 | 20.20% | 44.70% | 94% | 19% | 3% |
Chemotherapy | 6.2 | 6.2 | 1.9 | 6.40% | 34.50% | 90% | 39% | 1.40% | |
ORIENT-2 | PD-1 inhibitor | 7.2 | 7.2 | NA | 12.60% | NA | 54.30% | 2.02% | NA |
Chemotherapy | 6.2 | 6.2 | NA | 6.30% | NA | 90.80% | 39% | NA | |
RATIONALE 302 | PD-1 inhibitor | 6.9 | 8.6 | NA | 20.30% | NA | NA | 19% | 14% |
Chemotherapy | 6.9 | 6.3 | NA | 9.80% | NA | NA | 56% | 12% | |